Berglind Osk Einarsdottir

Berglind Osk Einarsdottir

Auto-generated profile, based on publicly available information

Berglind Osk Einarsdottir

Department of Biomedical Science, Faculty of Medicine, University of Iceland, Reykjavík, Iceland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2014 in Nature
Verified
Journal Article
Closed access
HGHelge Gad
Helge Gad
TKTobias Koolmeister
Tobias Koolmeister
AJAnn-Sofie Jemth
Ann-Sofie Jemth
SESaeed Eshtad
Saeed Eshtad
SJSylvain A Jacques
Sylvain A Jacques
THThomas Helleday
Thomas Helleday

6 July 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TLTaral R. Lunavat
Taral R. Lunavat
Lesley ChengLesley Cheng
Lesley Cheng
BEBerglind O. Einarsdottir
Berglind O. Einarsdottir
Roger Olofsson BaggeRoger Olofsson Bagge
Roger Olofsson Bagge
SMSomsundar Veppil Muralidharan
Somsundar Veppil Muralidharan
JLJan Olof Lötvall
Jan Olof Lötvall
The BRAF inhibitors vemurafenib and dabrafenib can be used to treat patients with metastatic melanomas harboring BRAFV600 mutations. Initial antitumoral responses are often seen, but drug-resistant clones with reactivation of the MEK–ERK pathway soon appear. Recently, the secretome of tumor-derived extracellular vesicles (EVs) has been ascribed important functions in cancers. To elucidate the possible functions of EVs in BRAF-mutant melanoma, we determined the RNA content of the EVs, including apoptotic bodies, microvesicles, and exosomes, released from such cancer cells after vemurafenib treatment. We found that vemurafenib significantly increased the total RNA and protein content of the released EVs and caused significant changes in the RNA profiles. RNA sequencing and quantitative PCR show that cells and EVs from vemurafenib-treated cell cultures and tumor tissues harvested from cell-derived and patient-derived xenografts harbor unique miRNAs, especially increased expression of miR-211–5p. Mechanistically, the expression of miR-211–5p as a result of BRAF inhibition was induced by increased expression of MITF that regulates the TRPM1 gene resulting in activation of the survival pathway. In addition, transfection of miR-211 in melanoma cells reduced the sensitivity to vemurafenib treatment, whereas miR-211–5p inhibition in a vemurafenib resistant cell line affected the proliferation negatively. Taken together, our results show that vemurafenib treatment induces miR-211–5p up-regulation in melanoma cells both in vitro and in vivo, as well as in subsets of EVs, suggesting that EVs may provide a tool to understand malignant melanoma progression. Significance The development of BRAF inhibitors is a notable clinical success, leading to rapid initial melanoma regression. However, response rates are tempered by a short duration of response in a majority of patients. This study has determined the effects of BRAF inhibition on mutant melanoma cells, as well as on the RNA contents in their vesicular secretome. Our data show the presence of miR-211–5p in all extracellular vesicular (EV) subsets upon treatment with BRAF inhibitors, which provides a fundamental starting point to understand the regulatory effects of molecules present in EVs, which may have implications for disease progression in patients receiving BRAF-targeted treatment.

1 December 2016 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
UBUlrika Warpman Berglund
Ulrika Warpman Berglund
KSK. Sanjiv
K. Sanjiv
HGH. Gad
H. Gad
CKC. Kalderén
C. Kalderén
TKT. Koolmeister
T. Koolmeister
THThomas Helleday
Thomas Helleday
Background Previously, we showed cancer cells rely on the MTH1 protein to prevent incorporation of otherwise deadly oxidised nucleotides into DNA and we developed MTH1 inhibitors which selectively kill cancer cells. Recently, several new and potent inhibitors of MTH1 were demonstrated to be non-toxic to cancer cells, challenging the utility of MTH1 inhibition as a target for cancer treatment. Material and methods Human cancer cell lines were exposed in vitro to MTH1 inhibitors or depleted of MTH1 by siRNA or shRNA. 8-oxodG was measured by immunostaining and modified comet assay. Thermal Proteome profiling, proteomics, cellular thermal shift assays, kinase and CEREP panel were used for target engagement, mode of action and selectivity investigations of MTH1 inhibitors. Effect of MTH1 inhibition on tumour growth was explored in BRAF V600E-mutated malignant melanoma patient derived xenograft and human colon cancer SW480 and HCT116 xenograft models. Results Here, we demonstrate that recently described MTH1 inhibitors, which fail to kill cancer cells, also fail to introduce the toxic oxidized nucleotides into DNA. We also describe a new MTH1 inhibitor TH1579, (Karonudib), an analogue of TH588, which is a potent, selective MTH1 inhibitor with good oral availability and demonstrates excellent pharmacokinetic and anti-cancer properties in vivo. Conclusion We demonstrate that in order to kill cancer cells MTH1 inhibitors must also introduce oxidized nucleotides into DNA. Furthermore, we describe TH1579 as a best-in-class MTH1 inhibitor, which we expect to be useful in order to further validate the MTH1 inhibitor concept.

8 September 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
BEBerglind O. Einarsdottir
Berglind O. Einarsdottir
Roger Olofsson BaggeRoger Olofsson Bagge
Roger Olofsson Bagge
JBJoydeep Bhadury
Joydeep Bhadury
HJHenrik Jespersen
Henrik Jespersen
JMJan Mattsson
Jan Mattsson
Jonas NilssonJonas Nilsson
Jonas Nilsson
The development of novel therapies against melanoma would benefit from individualized tumor models to ensure the rapid and accurate identification of biomarkers of therapy response. Previous studies have suggested that patient-derived xenografts (PDXes) could be useful. However, the utility of PDXes in guiding real-time treatment decisions has only been reported in anecdotal forms. Here tumor biopsies from patients with stage III and IV metastatic malignant melanoma were transplanted into immunocompromised mice to generate PDXes. 23/26 melanoma biopsies generated serially transplantable PDX models, and their histology, mutation status and expression profile resembled their corresponding patient biopsy. The potential treatment for one patient was revealed by an in vitro drug screen and treating PDXes with the MEK inhibitor trametinib. In another patient, the BRAF mutation predicted the response of both the patient and its corresponding PDXes to MAPK-targeted therapy. Importantly, in this unselected group of patients, the time from biopsy for generation of PDXes until death was significantly longer than the time required to reach the treatment phase of the PDXes. Thus, it could be clinically meaningful to use this type of platform for melanoma patients as a pre-selection tool in clinical trials.

22 May 2013 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
IRInga Reynisdóttir
Inga Reynisdóttir
AAAdalgeir Arason
Adalgeir Arason
BEBerglind O. Einarsdottir
Berglind O. Einarsdottir
HGHaukur Gunnarsson
Haukur Gunnarsson
JSJohan Staaf
Johan Staaf
RBRosa Bjork Barkardottir
Rosa Bjork Barkardottir
Amplification of 8p12‐p11 is relatively common in breast cancer and several genes within the region have been suggested to affect breast tumor progression. The aim of the study was to map the amplified 8p12‐p11 region in a large set of breast tumors in an effort to identify the genetic driver and to explore its impact on tumor progression and prognosis. Copy number alterations (CNAs) were mapped in 359 tumors, and gene expression data from 577 tumors (359 tumors included) were correlated with CNA, clinical–pathological factors, and protein expression (39 tumors). 8p12‐p11 was amplified in 11.4% of tumors. The smallest region of amplification harbored one full‐length gene, ZNF703. ZNF703 mRNA expression was significantly higher in estrogen receptor (ER)‐positive than ER‐negative tumors (P = 2 × 10−16), a reflection of high expression in luminal tumors. Forty‐eight percent of tumors with ZNF703 amplification were luminal B tumors in which the best correlation between DNA copy number and mRNA was seen (P = 1.2 × 10−7) as well as correlation between mRNA and protein expression (P = 0.02). High ZNF703 mRNA correlated with poor survival in patients with ER‐positive luminal B tumors (log rank P = 0.04). Furthermore, high ZNF703 mRNA expression correlated with poor outcome in patients with ZNF703 copy number neutral, ER‐positive, luminal B tumors (log rank P = 0.004). The results support ZNF703 as the driver gene of the 8p12 amplification and suggest that independent of amplification, high expression of the gene affects prognosis in luminal B tumors.

12 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LSLaufey Steingrimsdottir
Laufey Steingrimsdottir
THThorhallur Ingi Halldorsson
Thorhallur Ingi Halldorsson
KSKristin Siggeirsdottir
Kristin Siggeirsdottir
MCMary Frances Cotch
Mary Frances Cotch
BEBerglind O. Einarsdottir
Berglind O. Einarsdottir
GSGunnar Sigurdsson
Gunnar Sigurdsson
The significance of serum 25-hydroxyvitamin D [25(OH)D] concentrations for hip fracture risk of the elderly is still uncertain. Difficulties reaching both frail and healthy elderly people in randomized controlled trials or large cohort studies may in part explain discordant findings. We determined hazard ratios for hip fractures of elderly men and women related to serum 25(OH)D, including both the frail and the healthy segment of the elderly population. The AGES-Reykjavik Study is a prospective study of 5764 men and women, age 66–96 years, based on a representative sample of the population of Reykjavik, Iceland. Participation was 71.8%. Hazard ratios of incident hip fractures and baseline bone mineral density were determined according to serum concentrations of 25(OH)D at baseline. Mean follow-up was 5.4 years. Compared with referent values (50–75 nmol/L), hazard ratios for hip fractures were 2.24 (95% CI 1.63, 3.09) for serum 25(OH)D <30 nmol/L, adjusting for age, sex, body mass index, height, smoking, alcohol intake and season, and 2.08 (95% CI 1.51, 2.87), adjusting additionally for physical activity. No difference in risk was associated with 30–50 nmol/L or ≥75 nmol/L in either model compared with referent. Analyzing the sexes separately, hazard ratios were 2.61 (95% CI 1.47, 4.64) in men and 1.93 (95% CI 1.31, 2.84) in women. Values <30 nmol/L were associated with significantly lower bone mineral density of femoral neck compared with referent, z-scores -0.14 (95% CI −0.27, −0.00) in men and −0.11 (95% CI −0.22, −0.01) in women. Our results lend support to the overarching importance of maintaining serum 25(OH)D above 30 nmol/L for bone health of elderly people while potential benefits of having much higher levels could not be detected.